Mikael Dolsten withdrew from the Novo Nordisk Board of Directors election.

Bagsværd, Denmark, November 13, 2025 – It was announced today that Mikael Dolsten has decided not to stand for election to the Board of Directors at the extraordinary general meeting scheduled for November 14, 2025, as previously announced.

Mikael Dolsten, who most recently served as the Chief Scientific Officer at Pfizer, expressed in his notification to Novo Nordisk that despite his desire to participate, he has decided to withdraw his candidacy for membership on the Board of Directors and as an observer due to personal reasons unrelated to Novo Nordisk A/S and Novo Nordisk Foundation.

Novo Nordisk Foundation and Novo Holdings A/S have announced that they will not propose another candidate to replace Mikael Dolsten at the extraordinary general meeting. Instead, Novo Nordisk Foundation and Novo Holdings A/S have indicated that the upcoming Novo Nordisk Board of Directors aims to appoint and propose two new candidates along with the already nominated Helena Saxon. The other Board of Directors candidates previously announced will remain as is for the extraordinary general meeting on November 14, 2025.

If all proposed candidates are elected, following the extraordinary general meeting on November 14, 2026, the Board of Directors will be composed of Lars Rebien Sørensen (Chairman), Cees de Jong (Vice Chairman), Britt Meelby Jensen, Kasim Kutay, and Stephan Engels (Board members elected by the shareholders) alongside Elisabeth Dahl Christensen, Liselotte Hyveled, Mette Bøjer Jensen, and Thomas Rantzau (Board members elected by the employees).

Novo Nordisk, founded in 1923 and headquartered in Denmark, is a global healthcare company. Our aim is to drive change to defeat serious chronic diseases by leveraging our heritage in diabetes. We work by making scientific breakthroughs, expanding access to our medicines, and focusing on preventing and ultimately treating diseases. Novo Nordisk employs approximately 78,500 people in 80 countries and markets its products in around 170 countries. Novo Nordisk’s Class B shares are listed on Nasdaq Copenhagen (Novo-B), and its ADRs are traded on the New York Stock Exchange (NVO).